Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
GAITHERSBURG, Md., Jan. 13, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announced today that Chairman and Chief Executive Officer Evan Jones will present at the NobleCon12 - Noble Financial Capital Markets’ 12th Annual Investor Conference on January 20, 2016, at 10:30 a.m. Eastern Standard Time. The conference is being held at Club Med in Sandpiper Bay, Florida from January 17-20.
Following the conference on January 22, 2016, a high-definition video webcast of OpGen’s presentation and a copy of the presentation materials will be available on the Company's web site. In addition, a complete catalog of presentations will be available at Noble Financial websites: www.noblefcm.com, or www.nobleconference.com. Viewers will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on both the company's website and on the Noble websites for 90 days following the event.
About OpGen, Inc.
OpGen, Inc. (OPGN) is developing and deploying precision medicine tools for antibiotic stewardship management in global healthcare settings, adding real benefits to antimicrobial stewardship programs and assisting clinicians with more rapid information about life threatening infections. Using molecular testing and bioinformatics, OpGen offers a full portfolio of QuickFISH™ and Acuitas® products including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, and Acuitas Lighthouse™ MDRO Management System products. Its QuickFISH products are a suite of FDA-cleared and CE-marked diagnostics for rapid molecular testing of positive blood cultures designed to assure appropriate antibiotic therapy. Learn more at www.opgen.com
About Noble Financial Capital Markets
Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous “non-deal” corporate road shows and sector-specific conferences. Members: FINRA, SIPC, MSRB. www.noblefcm.com
Contacts:
OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
[email protected]
[email protected]
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]
or
Bruce Voss
(310) 691-7100
[email protected]
